<DOC>
	<DOCNO>NCT02358005</DOCNO>
	<brief_summary>Recently , It know efficacy botulinum toxin type A ( BTX-A ) extracorporeal shock wave therapy ( ESWT ) great BTX-A electrical stimulation management post-stroke spasticity upper limb . However , determine dose ESWT optimal adjuvant therapy BTX-A injection upper limb patient stroke . Therefore , aim study evaluate optimal dose ESWT botulinum toxin type A injection post-stroke spasticity</brief_summary>
	<brief_title>Optimal Dose Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection Post-stroke Spasticity</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<criteria>Male female Age ≥20 year inpatients Elbow flexor spasticity patient , confirm mainly due biceps brachii Modified Ashworth scale ( MAS ) ≥2 , At least 3month period stroke , Written inform consent obtain Fixed contracture and/or deformity elbow , Previous fracture paretic upper limb , Peripheral nervous system disorders/myopathies , Previous BTXA treatment and/or ESWT , Structural alteration soft tissue ( e.g. , fibrosis ) , Known allergy sensitivity study medication component Presence unstable medical condition uncontrolled systemic disease Any medical condition may put patient increase risk exposure botulinum toxin therapy . ( ex . Myasthenia gravis , EatonLambert syndrome , amyotrophic lateral sclerosis , significant disease might interface neuromuscular function . Bleeding tendency and/or anticoagulation therapy Presence infection skin disorder injection sit Females pregnant , nursing , plan pregnancy study Females childbearing potential ( include premenstrual woman ) , use reliable mean contraception Participant withdrawn study opinion investigator reason</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>